Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours
1998

Somatostatin Receptor Expression in Carcinoid Tumours

Sample size: 12 publication Evidence: moderate

Author Information

Author(s): 0 Nilsson, L Kolby, B Wangberg, A Wigander, H Billig, L William-Olsson, M Fjalling, E Forssell-Aronsson, H Ahliman

Primary Institution: Sahlgrenska University Hospital, University of Gothenburg, Sweden

Hypothesis

The study investigates the expression of somatostatin receptor subtypes in carcinoid tumours and their response to octreotide treatment.

Conclusion

Carcinoid tumours express multiple somatostatin receptor subtypes, and octreotide treatment significantly reduces hormonal symptoms and tumour markers.

Supporting Evidence

  • All patients had positive tumour imaging with octreotide scintigraphy.
  • Somatostatin receptor scintigraphy visualized tumours in all patients.
  • Octreotide treatment resulted in a significant reduction in urinary 5-HIAA levels.

Takeaway

Doctors looked at how certain receptors in carcinoid tumours work and found that a medicine called octreotide can help make patients feel better.

Methodology

The study analyzed tumour tissues from patients using Northern blotting and assessed the effects of octreotide treatment in both clinical and in vitro settings.

Limitations

The study primarily focused on a small number of patients with specific types of carcinoid tumours.

Participant Demographics

Patients included nine females and three males with midgut and foregut carcinoids.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication